Correction to: Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants.

Pestinger, Valerie; Smith, Matthew; Sillo, Toju; Findlay, John M; Laes, Jean-Francois; Martin, Gerald; Middleton, Gary; Taniere, Phillipe; Beggs, Andrew D

Pestinger, Valerie; Smith, Matthew; Sillo, Toju; Findlay, John M; Laes, Jean-Francois; Martin, Gerald; Middleton, Gary; Taniere, Phillipe; Beggs, Andrew D.

Afiliação

Pestinger V; Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK.
Smith M; Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Sillo T; Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK.
Findlay JM; Northern Devon Healthcare NHS Trust, Barnstaple, UK.
Laes JF; OncoDNA, Gosselies, Belgium.
Martin G; PierianDx, St. Louis, MO, USA.
Middleton G; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
Taniere P; Queen Elizabeth Hospital Birmingham, Birmingham, UK.
Beggs AD; Surgical Research Laboratory, Institute of Cancer and Genomic Sciences, University of Birmingham, Vincent Drive, Birmingham, B15 2TT, UK. a.beggs@bham.ac.uk.

Mol Diagn Ther ; 24(4): 505, 2020 Aug.

Article em En | MEDLINE | ID: mdl-32572786

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Diagn Ther Assunto da revista: BIOLOGIA MOLECULAR / FARMACOLOGIA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google